Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Semaglutide offers a strong option for improving blood sugar and supporting weight loss. Higher doses like 25 mg and 50 mg ...

Over the nine-week trial, participants taking semaglutide started at a dose of 0.25 mg per week, which gradually increased to 1.0 mg in the final week -- a much lower dose than what’s typically ...

This can help mitigate some semaglutide side effects. The recommended maintenance dose of Wegovy is 2.4 milligrams (mg) weekly. But not everyone will need such a high dose to achieve their weight ...

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...

The treatment group received 0.5 mg of semaglutide per week ... of which 34 were female, and 14 were male. On average, the participants exhibited moderate AUD severity. The mean age of the ...

In this review of 37.1 million patients, the incidence rate of NAION among semaglutide users was 14.5 and 8.7 per 100,000 person-years using the sensitive and specific NAION definitions ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.